EKR Therapeutics Named Private Company of the Year By New Jersey Technology Council

BEDMINSTER, N.J.--()--EKR Therapeutics, Inc., a specialty pharmaceutical company focused on commercializing acute-care hospital products, today announced that it has been named Private Company of the Year by the New Jersey Technology Council (NJTC), a more than 1,200 member non-for-profit organization supporting growth in New Jersey's various technology sectors including health sciences.

The honor was bestowed upon EKR on November 18, 2009 at the NJTC black-tie Gala Awards ceremony. Held annually, the NJTC Gala Awards attracts hundreds of attendees to publicly recognize and celebrate highly successful companies in different categories.

“We are delighted that NJTC recognized EKR for our success in providing critical-care products for the hospital setting,” said Howard Weisman, EKR’s CEO and President. “Being named Private Company of the Year, in the NJTC Super Awards category, is a true testament to the dedication of the EKR team. It is through the spirit and hard work of our entire organization that EKR has grown from a start-up, one product company in June 2006 to now having over 100 employees, a greatly expanded portfolio of acute-care products, and revenues well in excess of $200 million.”

About EKR Therapeutics

EKR Therapeutics is a specialty pharmaceutical company focused on acquiring, developing and maximizing the potential utility of critical-care hospital products offering broader therapeutic options and greater control to improve in-patient care, speed recovery, and achieve optimal outcomes. Backed by the strength of its award winning management team, the dedication of its field force of product specialists and its commitment to excellence in customer service and medical education, EKR has been organized to be a class leader in commercializing products to address unmet and under-satisfied medical needs or to otherwise enhance the therapeutic value of acute-care products. For additional information about EKR visit the Company’s website at www.ekrtx.com.

Contacts

EKR Therapeutics
Stuart Z. Levine, Ph.D.
Director, Strategic Communications
Investor Relations
877-435-2524
s.levine@ekrtx.com

Contacts

EKR Therapeutics
Stuart Z. Levine, Ph.D.
Director, Strategic Communications
Investor Relations
877-435-2524
s.levine@ekrtx.com